Bioject gets second deal with Amgen:
This article was originally published in Clinica
Bioject Medical Technologies has formed a second agreement with Amgen for Bioject's needle-free injection system for certain of Amgen's therapeutics. Bioject will get $1 million upfront, as well as development milestones and other payments. Amgen will get exclusive rights to the Portland, Oregon-based company's modified B2000 needle-free system. Under the terms of the new contract, Amgen's potential use of the needle-free systems is expanded. It also includes product licensing and commercial supply terms. The initial contract was signed in March 2000 and covered Bioject's Iject systems.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.